Rhamnazin

Research use only, not for human use.

Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC50 of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy. Rhamnazin shows antioxidant and anti-inflammatory properties.

Rhamnazin is a natural product.

Cell Migration Assay Cell Line:HUVECs Concentration:0, 10, 15 and 20 μM Incubation Time:6 h Result:Strongly inhibited the migration of HUVECs.Western Blot Analysis Cell Line:HUVECs Concentration:0, 10, 15 and 20 μM Incubation Time:24 h Result:Decreased VEGF binding to VEGFR2. Reduced VEGF-stimulated phosphorylation of VEGFR2 and its downstream MAPK, AKT, and STAT3 in HUVECs in a concentrationdependent manner.Cell Proliferation Assay Cell Line:HCC1937, T-47D, SK-BR-3, MCF-7 and MDA-MB-231 Concentration:0, 10, 15, 20, 30 and 40 μM Incubation Time:24 h Result:Inhibited cell growth with IC50s of 19, 27, 32, 41 and 64 μM against MDA-MB-231, MCF-7, SK-BR-3, T-47D and HCC1937 in the presence of VEGF, respectively.

Animal Model:BALB/c nude mice, breast cancer xenograft model Dosage:200 mg/kg Administration:Intragastric administration, daily for 25 days Result:Dramatically suppressed tumor volumes by 47% compared with the vehicle group. Showed a significant reduction of pVEGFR2Tyr951-positive cells in tumors. Resulted in downregulation of VEGFR2 downstream molecules phosphorylation including MAPK, AKT and STAT3.

———

Others

Other Targets

Others

———

———

552-54-5

330.29

C17H14O7

>98% (HPLC)

———

O=C1C(O)=C(OC2=CC(OC)=CC(O)=C12)C=3C=CC(O)=C(OC)C3

——

(-20℃)

With Ice Pack

≥ 2 years